PRME:NSD-Prime Medicine, Inc. Common Stock (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 3.98

Change

-0.02 (-0.50)%

Market Cap

N/A

Volume

0.83M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-18 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
REGN Regeneron Pharmaceuticals Inc

-7.94 (-0.69%)

USD 127.14B
VRTX Vertex Pharmaceuticals Inc

-7.10 (-1.48%)

USD 125.27B
ALNY Alnylam Pharmaceuticals Inc

-1.31 (-0.48%)

USD 35.24B
ARGX argenx NV ADR

+6.84 (+1.31%)

USD 32.19B
MRNA Moderna Inc

-2.13 (-2.96%)

USD 26.25B
SMMT Summit Therapeutics PLC

-1.66 (-6.33%)

USD 23.47B
BGNE BeiGene Ltd

-0.23 (-0.12%)

USD 21.94B
RPRX Royalty Pharma Plc

-0.03 (-0.11%)

USD 16.45B
BMRN Biomarin Pharmaceutical Inc

+0.59 (+0.84%)

USD 16.16B
UTHR United Therapeutics Corporatio..

-2.43 (-0.70%)

USD 15.09B

ETFs Containing PRME

XDNA 5.77 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -55.08% 22% F 13% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -55.08% 22% F 13% F
Trailing 12 Months  
Capital Gain -65.92% 20% F 12% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -65.92% 20% F 12% F
Trailing 5 Years  
Capital Gain -80.33% 40% F 15% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -80.33% 39% F 15% F
Average Annual (5 Year Horizon)  
Capital Gain -19.41% 30% F 17% F
Dividend Return -19.41% 30% F 17% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 24.77% 94% A 70% C-
Risk Adjusted Return -78.38% 16% F 10% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector